Lung cancer is driven by different molecular alterations, including the epidermal growth factor receptor (EGFR) mutations and the rearrangements of the anaplastic lymphoma kinase (ALK) and the c-ros1 (ROS1) genes. This evidence concerns the gene ALK and lung cancer.